© 2023 GeneDx All rights reserved.
September 22, 2023
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 11, 2023
GeneDx Announces Evolution of Executive Leadership Team
September 6, 2023
GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced
August 21, 2023
GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine
August 8, 2023
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 8, 2023
GeneDx Reports Second Quarter 2023 Financial Results and Business Highlights
August 7, 2023
PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care
July 19, 2023
GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options
July 18, 2023
GeneDx to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
June 28, 2023
GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundation’s Mitochondrial Medicine Symposium
Displaying 1 - 10 of 33
